This review highlights the diagnosis, genetic testing, and management of dystrophinopathies, emphasizing the role of steroid therapy and ongoing research in gene expression alteration.
Answers are grounded in this paper and cite their sources.
May support steroid use in dystrophinopathies; leaves open gene therapy optimization for prospective trials.
The dystrophinopathies fall along a spectrum of muscular dystrophy phenotypes, with variable involvement of skeletal and cardiac muscle. The diagnosis of dystrophinopathy should be suspected in any patient with a highly elevated creatine kinase level beyond the context of rhabdomyolysis secondary to toxic or metabolic myopathy. Genetic testing for dystrophinopathy is highly sensitive and specific, and identifying a proband will often lead to implications for several relatives at risk for cardiomyopathy, weakness, or anesthetic reactions. Management of the dystrophinopathies is focused primarily on supportive care, although steroid therapy has changed the natural history of Duchenne muscular dystrophy and it is now standard-of-care internationally. An exciting and ongoing area of investigation of the dystrophinopathies is focused on the potential for altering gene expression, as a way of improving muscle health and slowing the rate of muscle degeneration.
No takes yet. Share an insight, caveat, or question.
Brandsema et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: